BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

800 related articles for article (PubMed ID: 29408569)

  • 1. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
    Li G; Liu D; Kimchi ET; Kaifi JT; Qi X; Manjunath Y; Liu X; Deering T; Avella DM; Fox T; Rockey DC; Schell TD; Kester M; Staveley-O'Carroll KF
    Gastroenterology; 2018 Mar; 154(4):1024-1036.e9. PubMed ID: 29408569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combretastatin A-1 phosphate, a microtubule inhibitor, acts on both hepatocellular carcinoma cells and tumor-associated macrophages by inhibiting the Wnt/β-catenin pathway.
    Mao J; Wang D; Wang Z; Tian W; Li X; Duan J; Wang Y; Yang H; You L; Cheng Y; Bian J; Chen Z; Yang Y
    Cancer Lett; 2016 Sep; 380(1):134-43. PubMed ID: 27349166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.
    Qi X; Wu F; Kim SH; Kaifi JT; Kimchi ET; Snyder H; Illendula A; Fox T; Kester M; Staveley-O'Carroll KF; Li G
    FASEB J; 2022 Apr; 36(4):e22250. PubMed ID: 35294071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice.
    Wei Y; Lao XM; Xiao X; Wang XY; Wu ZJ; Zeng QH; Wu CY; Wu RQ; Chen ZX; Zheng L; Li B; Kuang DM
    Gastroenterology; 2019 May; 156(6):1890-1904.e16. PubMed ID: 30711627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8
    Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
    J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful chemoimmunotherapy against hepatocellular cancer in a novel murine model.
    Li G; Liu D; Cooper TK; Kimchi ET; Qi X; Avella DM; Li N; Yang QX; Kester M; Rountree CB; Kaifi JT; Cole DJ; Rockey DC; Schell TD; Staveley-O'Carroll KF
    J Hepatol; 2017 Jan; 66(1):75-85. PubMed ID: 27520877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tramadol suppresses growth of orthotopic liver tumors via promoting M1 macrophage polarization in the tumor microenvironment.
    Wang L; Guo W; Guan H; Yan N; Cai X; Zhu L
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4205-4218. PubMed ID: 38041778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats.
    Wen X; Reynolds L; Mulik RS; Kim SY; Van Treuren T; Nguyen LH; Zhu H; Corbin IR
    Gastroenterology; 2016 Feb; 150(2):488-98. PubMed ID: 26484708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.
    Liang S; Ma HY; Zhong Z; Dhar D; Liu X; Xu J; Koyama Y; Nishio T; Karin D; Karin G; Mccubbin R; Zhang C; Hu R; Yang G; Chen L; Ganguly S; Lan T; Karin M; Kisseleva T; Brenner DA
    Gastroenterology; 2019 Mar; 156(4):1156-1172.e6. PubMed ID: 30445007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
    Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.
    Wan S; Zhao E; Kryczek I; Vatan L; Sadovskaya A; Ludema G; Simeone DM; Zou W; Welling TH
    Gastroenterology; 2014 Dec; 147(6):1393-404. PubMed ID: 25181692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
    Wu Q; Zhou W; Yin S; Zhou Y; Chen T; Qian J; Su R; Hong L; Lu H; Zhang F; Xie H; Zhou L; Zheng S
    Hepatology; 2019 Jul; 70(1):198-214. PubMed ID: 30810243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.